BNP Paribas analyst Matthew Akers initiated coverage of Amentum with an Underperform rating and $22 price target. The firm expects Amentum's organic growth and margins to fall behind peers and thinks a discounted valuation is warranted, the analyst tells investors in a research note. Only modest margin expansion beyond the current 8% level is likely, the firm adds.
